Literature DB >> 6608049

Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil.

S H Berger, M T Hakala.   

Abstract

The purpose of this study was to compare the pools of free FdUMP derived from 5-fluorouracil (FUra) and of dUMP synthesized de novo in Hep-2 and S-180 cells, their relationship to inhibition of thymidylate synthase (dTMP synthase; EC 2.1.1.45), and the effect of excess folinic acid (CF) on these parameters. These cells differ 50-fold in their sensitivity to FUra and, in the absence of thymidine, dTMP synthase is the growth-limiting site of action of FUra in S-180 cells, but in Hep-2 cells this site becomes growth-limiting only in the presence of excess folates. In both cells after a 3-hr incubation with varied concentrations of FUra, FdUMP comprised only 0.1-0.2% of the total acid-soluble pools derived from FUra. The changes in dUMP and FdUMP pools paralleled each other, dUMP being 1000-2000 times higher than FdUMP. The pools of dUMP increased only when dTMP synthase was significantly inhibited. This occurred in S-180 cells above 3 microM FUra and in Hep-2 cells above 30 microM, where the residual dTMP synthase was similar in both cells. Under these conditions, the dUMP and FdUMP pools in Hep-2 cells were 2 and 4 times higher, respectively, than in S-180 cells. After FUra removal, both pools continued to increase, dUMP and FdUMP pools in Hep-2 cells rising 6-fold and 10-fold higher, respectively, than in S-180 cells. The dTMP synthase inhibition and the high nucleotide pools in Hep-2 were short-lived, whereas in S-180 cells the inhibition and the pools were maintained longer. Excess CF retarded the recovery of dTMP synthase after FUra removal only in Hep-2 cells and led to a further increase in dUMP and FdUMP pools in these cells, while having no effect in S-180 cells. These data indicate that a high capacity of cells to accumulate free FdUMP does not alone guarantee that dTMP synthase inhibition will be growth-limiting. The relationship shown here between excess CF, dTMP synthase recovery, and the nucleotide pools suggests that some cell types, such as Hep-2, in spite of high levels of FdUMP, require in addition an excess of folates to retard dTMP synthase recovery and make it growth-limiting.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608049

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

1.  In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Uracil in DNA: consequences for carcinogenesis and chemotherapy.

Authors:  Sondra H Berger; Douglas L Pittman; Michael D Wyatt
Journal:  Biochem Pharmacol       Date:  2008-07-01       Impact factor: 5.858

3.  Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).

Authors:  Patricia M LoRusso; Sucharu Prakash; Antoinette Wozniak; Lawrence Flaherty; Mark Zalupski; Anthony Shields; Howard Sands; Ralph Parchment; Bhaskara Jasti
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

4.  Evolution of metamorphism in thymidylate synthases within the primate lineages.

Authors:  BeiBei Luo; Saphronia R Johnson; Lukasz Lebioda; Sondra H Berger
Journal:  J Mol Evol       Date:  2011-02-12       Impact factor: 2.395

5.  A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.

Authors:  Robert P Whitehead; Jacqueline K Benedetti; James L Abbruzzese; Bach Ardalan; Stephen Williamson; Ellen R Gaynor; Stanley P Balcerzak; John S Macdonald
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

6.  Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.

Authors:  R M Mader; G G Steger; B Rizovski; A E Sieder; G Locker; M F Gnant; R Jakesz; H Rainer
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

7.  Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.

Authors:  G G Steger; R M Mader; M P Djavanmard; M F Gnant; G Locker; C Marosi; H Rainer; R Jakesz
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.

Authors:  B Mitrovski; J Pressacco; S Mandelbaum; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma.

Authors:  J C Nadal; C J van Groeningen; H M Pinedo; G J Peters
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

10.  Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.

Authors:  Hong-Yun Zhao; Gong-Yan Chen; Yan Huang; Xiao-Li Li; Ji-Feng Feng; Mei-Qi Shi; Ying Cheng; Li-Xia Ma; Yi-Ping Zhang; Cui-Ping Gu; Xiang-Qun Song; Da Zhou; Li Zhang
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.